The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. | The emergence of ...

Verastem, Inc. shifts focus to VS-7375 for KRAS G12D tumors after ending RAMP-203. Click to learn about VSTM's key catalysts ...

Oncology announced that following evaluation of interim data from the RAMP 203 clinical trial in advanced KRAS G12C-mutated ...

Verastem Oncology said it will discontinue its RAMP 203 trial of a lung cancer treatment. The Boston biopharmaceutical company said Monday it plans to focus resources instead on clinical development ...

As of the cutoff date of March 31, 2025, GenFleet reported that no dose-limiting toxicities (DLTs) were observed across all dose levels (100-900 mg QD), and the treatment-related adverse events (TRAEs ...

Investing.com -- Verastem Inc (NASDAQ:VSTM) stock dropped 3.4% in after-hours trading Monday following the company’s announcement that it will discontinue its RAMP 203 clinical trial in advanced KRAS ...

Verastem Oncology has shared a different spin on what its near-approval treatment for low-grade serous ovarian cancer (LGSOC) could mean for patients, publishing survey results that dig into the ...

We expect investors to focus on Verastem Oncology’s VSTM progress with the development of its pipeline candidates being studied for various cancer indications when it reports first-quarter 2025 ...

It was back in October of 2022 when Verastem (NASDAQ:VSTM) updated investors on their RAMP clinical trials, which included their recurrent low-grade serous ovarian cancer “LGSOC”, KRAS G12V-Mutant non ...

BTIG raised the firm’s price target on Verastem (VSTM) to $20 from $13 and keeps a Buy rating on the shares after the company announced the FDA accepted its new drug application filing for ...

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced it has submitted a ...

Every investor in Verastem, Inc. (NASDAQ:VSTM) should be aware of the most powerful shareholder groups. With 60% stake, institutions possess the maximum shares in the company. That is, the group ...